Nexalin Next-Gen Insomnia Neurostimulator Nears FDA Presentation Stage
Nexalin is planning to present its gen-2 and gen-3 to the FDA in Q1 for the treatment of anxiety and insomnia. Waveform power will be upped from 4 milliamps to 15.
Read More
Author: Sree Roy
Why Might Sleep Apnea to Lead to Alzheimer’s Disease? Mouse Study Explains Link
Sleep deprivation alone in mice caused only mild cognitive impairment, so what causes the selective degeneration of neurons that characteristically die in dementia?
Read More
Apnimed Secures Funding for Phase 3 Trials of Sleep Apnea Drug Candidate AD109
Enrollment for the clinical trials is expected to begin in the second quarter of 2023, pending discussions with the FDA.
Read More
KemPharm Starts Phase 2 Trial Investigating KP1077 for Idiopathic Hypersomnia
KemPharm expects to enroll about 48 adult patients with IH in more than 30 centers in the United States.
Read More
CPAP Tracking Module Defines ‘Adherence’ Differently
Researchers have developed a new adherence metric alongside a new tool for monitoring adherence to CPAP therapy for patients and physicians.
Read More